63 is the total number of securities Foresite Capital Management III, LLC has owned. The longest Foresite Capital Management III, LLC has owned a single stock is 24 quarters.
| Period | Weighting | Quarter | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
| EPZM | Epizyme, Inc. | 24 | 24 | 2.02% | 6.06% | 17.63% | Q4 2015 | Q3 2021 | 24 |
| XLRN | Acceleron Pharma Inc. | 20 | 2 | 0.20% | 5.86% | 25.92% | Q4 2015 | Q3 2021 | 22 |
| CBAY | CymaBay Therapeutics, ... | 10 | 10 | 1.33% | 7.16% | 17.57% | Q3 2017 | Q3 2022 | 20 |
| AERI | Aerie Pharmaceuticals,... | 18 | 18 | 5.03% | 22.26% | 33.48% | Q4 2015 | Q1 2020 | 18 |
| ASND | Ascendis Pharma A/S | 13 | 4 | 0.20% | 13.01% | 47.81% | Q4 2016 | Q3 2022 | 17 |
| ALDR | Alder BioPharmaceutica... | 16 | 16 | 6.73% | 13.47% | 27.42% | Q4 2015 | Q3 2019 | 16 |
| NTRA | Natera, Inc. | 11 | 1 | 0.97% | 10.35% | 21.51% | Q1 2017 | Q3 2022 | 16 |
| AIMT | Aimmune Therapeutics, ... | 16 | 16 | 1.74% | 5.55% | 8.12% | Q4 2015 | Q3 2019 | 16 |
| VRNA | Verona Pharma PLC. | 7 | 1 | 0.66% | 8.32% | 29.98% | Q2 2017 | Q3 2022 | 15 |
| WVE | WAVE Life Sciences Ltd. | 15 | 15 | 0.55% | 6.11% | 19.96% | Q4 2015 | Q2 2019 | 15 |
| BPMC | Blueprint Medicines Co... | 12 | 2 | 3.42% | 9.21% | 17.31% | Q4 2016 | Q2 2020 | 14 |
| MYOK | Myokardia, Inc. | 13 | 13 | 3.48% | 12.23% | 40.54% | Q3 2017 | Q3 2020 | 13 |
| ACRS | Aclaris Therapeutics, ... | 6 | 2 | 0.64% | 11.76% | 48.80% | Q4 2016 | Q3 2021 | 13 |
| IMMU | Immunomedics, Inc. | 13 | 13 | 0.43% | 10.31% | 20.75% | Q1 2017 | Q1 2020 | 13 |
| BOLD | Audentes Therapeutics,... | 8 | 3 | 0.44% | 2.68% | 7.82% | Q3 2016 | Q4 2019 | 11 |
| AKAOQ | Achaogen, Inc. | 10 | 10 | 0.34% | 6.82% | 14.76% | Q4 2016 | Q1 2019 | 10 |
| BHVN | Biohaven Pharmaceutica... | 8 | 1 | 0.24% | 1.09% | 3.37% | Q2 2017 | Q1 2020 | 10 |
| TOCA | Tocagen, Inc. | 9 | 9 | 0.30% | 1.14% | 2.96% | Q2 2017 | Q2 2019 | 9 |
| BDSI | BioDelivery Sciences I... | 6 | 3 | 0.01% | 0.39% | 0.87% | Q1 2016 | Q2 2019 | 9 |
| FGEN | FibroGen, Inc. | 6 | 2 | 0.83% | 5.44% | 13.18% | Q1 2017 | Q2 2021 | 8 |
| ZFGN | Zafgen, Inc. | 7 | 7 | 0.27% | 2.31% | 6.14% | Q4 2015 | Q2 2017 | 7 |
| RCUS | Arcus Biosciences, Inc. | 6 | 6 | 3.56% | 7.34% | 10.60% | Q1 2018 | Q2 2019 | 6 |
| REPL | Replimune Group, Inc. | 6 | 6 | 2.52% | 2.95% | 3.75% | Q3 2018 | Q4 2019 | 6 |
| ARDX | Ardelyx, Inc. | 3 | 1 | 0.06% | 1.34% | 3.90% | Q1 2016 | Q3 2018 | 6 |
| GBT | Global Blood Therapeut... | 5 | 5 | 0.40% | 6.49% | 13.19% | Q4 2015 | Q4 2016 | 5 |
| NSTG | NanoString Technologie... | 5 | 5 | 0.61% | 2.56% | 4.54% | Q2 2016 | Q2 2017 | 5 |
| AKTX | Akari Therapeutics, PLC | 5 | 5 | 0.60% | 1.89% | 3.39% | Q4 2015 | Q4 2016 | 5 |
| SGMO | Sangamo Therapeutics, ... | 3 | 1 | 0.44% | 1.09% | 2.55% | Q1 2016 | Q3 2018 | 5 |
| NVAX | Novavax, Inc. | 5 | 5 | 0.40% | 0.88% | 1.44% | Q3 2020 | Q3 2021 | 5 |
| NTLA | Intellia Therapeutics,... | 4 | 4 | 0.81% | 5.52% | 11.19% | Q2 2016 | Q1 2017 | 4 |
| BLCM | Bellicum Pharmaceutica... | 2 | 2 | 1.49% | 2.35% | 4.35% | Q1 2016 | Q2 2017 | 4 |
| LPCN | Lipocine Inc. | 4 | 4 | 0.63% | 2.04% | 3.78% | Q4 2015 | Q3 2016 | 4 |
| OREX | Orexigen Therapeutics,... | 4 | 4 | 0.39% | 1.76% | 4.58% | Q4 2015 | Q3 2016 | 4 |
| SLDB | Solid Biosciences Inc. | 4 | 4 | 0.44% | 1.60% | 2.59% | Q1 2018 | Q4 2018 | 4 |
| PACB | Pacific Biosciences of... | 3 | 1 | 0.33% | 1.20% | 1.66% | Q2 2017 | Q3 2018 | 4 |
| NeuroDerm Ltd. | 3 | 3 | 2.25% | 3.13% | 3.96% | Q4 2015 | Q2 2016 | 3 | |
| PTGX | Protagonist Therapeuti... | 3 | 3 | 1.70% | 2.65% | 3.31% | Q3 2016 | Q1 2017 | 3 |
| LOXO | Loxo Oncology, Inc. | 3 | 3 | 1.27% | 1.94% | 2.95% | Q1 2017 | Q3 2017 | 3 |
| DERM | Dermira, Inc. | 3 | 3 | 0.32% | 1.43% | 2.31% | Q1 2017 | Q3 2017 | 3 |
| OREXQ | Orexigen Therapeutics,... | 3 | 3 | 0.19% | 0.35% | 0.50% | Q4 2016 | Q2 2017 | 3 |
| Oric Pharmaceuticals, ... | 2 | 2 | 9.25% | 14.40% | 19.55% | Q3 2020 | Q4 2020 | 2 | |
| RGLS | Regulus Therapeutics Inc. | 2 | 2 | 4.23% | 4.90% | 5.56% | Q4 2015 | Q1 2016 | 2 |
| XENT | Intersect ENT, Inc. | 2 | 2 | 2.48% | 3.23% | 3.99% | Q4 2015 | Q1 2016 | 2 |
| AVXS | Avexis, Inc. | 2 | 2 | 2.48% | 3.01% | 3.54% | Q1 2016 | Q2 2016 | 2 |
| MNTA | Momenta Pharmaceutical... | 1 | 1 | 2.21% | 2.73% | 3.25% | Q3 2016 | Q1 2017 | 2 |
| IRTC | iRhythm Technologies, ... | 2 | 2 | 1.01% | 1.59% | 2.17% | Q4 2016 | Q1 2017 | 2 |
| EDIT | Editas Medicine, Inc. | 1 | 1 | 0.39% | 1.16% | 1.94% | Q1 2016 | Q4 2016 | 2 |
| ARGX | argenx SE | 2 | 2 | 1.10% | 1.16% | 1.22% | Q2 2017 | Q3 2017 | 2 |
| RGNX | Regenxbio Inc. | 2 | 2 | 0.84% | 1.15% | 1.47% | Q4 2015 | Q1 2016 | 2 |
| SYRS | Syros Pharmaceuticals,... | 2 | 2 | 0.39% | 1.13% | 1.87% | Q2 2016 | Q3 2016 | 2 |
| DMTX | Dimension Therapeutics... | 2 | 2 | 0.60% | 0.79% | 0.98% | Q4 2015 | Q1 2016 | 2 |
| IMGN | ImmunoGen, Inc. | 2 | 2 | 0.28% | 0.40% | 0.52% | Q4 2015 | Q1 2016 | 2 |
| ORIC | Oric Pharmaceuticals, ... | 1 | 1 | 14.90% | 14.90% | 14.90% | Q2 2020 | Q2 2020 | 1 |
| XLRN | Acceleron Pharma Inc. | 1 | 1 | 4.32% | 4.32% | 4.32% | Q4 2015 | Q4 2015 | 1 |
| DYAX | Dyax Corp | 1 | 1 | 1.86% | 1.86% | 1.86% | Q4 2015 | Q4 2015 | 1 |
| MDGL | Madrigal Pharmaceutica... | 1 | 1 | 1.24% | 1.24% | 1.24% | Q3 2017 | Q3 2017 | 1 |
| JNCE | Jounce Therapeutics, Inc. | 1 | 1 | 0.77% | 0.77% | 0.77% | Q1 2017 | Q1 2017 | 1 |
| Immunomedics, Inc. | 1 | 1 | 0.76% | 0.76% | 0.76% | Q2 2018 | Q2 2018 | 1 | |
| Immunomedics, Inc. | 1 | 1 | 0.76% | 0.76% | 0.76% | Q2 2018 | Q2 2018 | 1 | |
| Achaogen, Inc. | 1 | 1 | 0.57% | 0.57% | 0.57% | Q1 2018 | Q1 2018 | 1 | |
| INFI | Infinity Pharmaceutica... | 1 | 1 | 0.38% | 0.38% | 0.38% | Q2 2017 | Q2 2017 | 1 |
| RARX | Ra Pharmaceuticals, Inc. | 1 | 1 | 0.06% | 0.06% | 0.06% | Q1 2018 | Q1 2018 | 1 |
| ABEO | Abeona Therapeutics, Inc. | 1 | 1 | 0.04% | 0.04% | 0.04% | Q2 2017 | Q2 2017 | 1 |
Download | |||||||||
The securities at the top of the list , including Epizyme, Inc., Acceleron Pharma Inc., and CymaBay Therapeutics, Inc., are the highest-conviction holdings of Foresite Capital Management III, LLC.
The conviction is calculated by counting the number of quarters a security has been reported by Foresite Capital Management III, LLC. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Foresite Capital Management III, LLC owns currently or has owned in the past.